Formulation and evaluation of fluconazole emulgels for potential treatment of vaginal candidiasis

Localised treatment of vaginal candidiasis could improve the therapeutic outcomes of patients with vaginal candidiasis as well as reduce drug dosage and dosing interval. The aim of the research project was to develop fluconazole emulgel formulations, and evaluate their physicochemical, drug release,...

Full description

Bibliographic Details
Main Authors: Oriyomi Temitayo Ogedengbe, Oluwadamilola Miriam Kolawole
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Heliyon
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024042373
_version_ 1797224118052978688
author Oriyomi Temitayo Ogedengbe
Oluwadamilola Miriam Kolawole
author_facet Oriyomi Temitayo Ogedengbe
Oluwadamilola Miriam Kolawole
author_sort Oriyomi Temitayo Ogedengbe
collection DOAJ
description Localised treatment of vaginal candidiasis could improve the therapeutic outcomes of patients with vaginal candidiasis as well as reduce drug dosage and dosing interval. The aim of the research project was to develop fluconazole emulgel formulations, and evaluate their physicochemical, drug release, antifungal, safety, and stability profile, for potential treatment of vaginal candidiasis. Xanthan gum and HPMC E5LV-based fluconazole emulgels were prepared using the spontaneous emulsification method and their physicochemical properties, drug content, drug release profile, anti-fungal activity against Candida albicans, in vivo vaginal biocompatibility and stability profile were evaluated using standard protocols. The fluconazole emulgels exhibited satisfactory properties: pH: 5.2–5.4; spreadability: 1.6–2.5 cm; apparent viscosity: 85–314 cP; zone of inhibition against Candida albicans: 22–38 mm; drug content: 91–102 %, and vaginal biocompatibility. All the studied fluconazole emulgels exhibited controlled fluconazole release over 6 h and their drug release kinetics fitted well with Korsmeyer-Peppas model. HPMC-based emulgels exhibited unsatisfactory real-time stability profile. To our knowledge, this is the first report where xanthan gum and HPMC E5LV-based fluconazole emulgels have been studied for possible treatment of vaginal candidiasis. Xanthan gum-based fluconazole emulgels are promising drug formulations that could reduce the drug dosage and dosing frequency. In addition, they could serve as alternative dosage forms to Flucos® gel.
first_indexed 2024-04-24T13:48:02Z
format Article
id doaj.art-37d564b4f0924a4fa56683a73c034797
institution Directory Open Access Journal
issn 2405-8440
language English
last_indexed 2024-04-24T13:48:02Z
publishDate 2024-03-01
publisher Elsevier
record_format Article
series Heliyon
spelling doaj.art-37d564b4f0924a4fa56683a73c0347972024-04-04T05:07:00ZengElsevierHeliyon2405-84402024-03-01106e28206Formulation and evaluation of fluconazole emulgels for potential treatment of vaginal candidiasisOriyomi Temitayo Ogedengbe0Oluwadamilola Miriam Kolawole1Department of Pharmaceutics and Pharmaceutical Technology, University of Lagos, NigeriaCorresponding author.; Department of Pharmaceutics and Pharmaceutical Technology, University of Lagos, NigeriaLocalised treatment of vaginal candidiasis could improve the therapeutic outcomes of patients with vaginal candidiasis as well as reduce drug dosage and dosing interval. The aim of the research project was to develop fluconazole emulgel formulations, and evaluate their physicochemical, drug release, antifungal, safety, and stability profile, for potential treatment of vaginal candidiasis. Xanthan gum and HPMC E5LV-based fluconazole emulgels were prepared using the spontaneous emulsification method and their physicochemical properties, drug content, drug release profile, anti-fungal activity against Candida albicans, in vivo vaginal biocompatibility and stability profile were evaluated using standard protocols. The fluconazole emulgels exhibited satisfactory properties: pH: 5.2–5.4; spreadability: 1.6–2.5 cm; apparent viscosity: 85–314 cP; zone of inhibition against Candida albicans: 22–38 mm; drug content: 91–102 %, and vaginal biocompatibility. All the studied fluconazole emulgels exhibited controlled fluconazole release over 6 h and their drug release kinetics fitted well with Korsmeyer-Peppas model. HPMC-based emulgels exhibited unsatisfactory real-time stability profile. To our knowledge, this is the first report where xanthan gum and HPMC E5LV-based fluconazole emulgels have been studied for possible treatment of vaginal candidiasis. Xanthan gum-based fluconazole emulgels are promising drug formulations that could reduce the drug dosage and dosing frequency. In addition, they could serve as alternative dosage forms to Flucos® gel.http://www.sciencedirect.com/science/article/pii/S2405844024042373Fluconazole emulgelsAntifungalPhysicochemicalControlled drug releaseIn vivo vaginal biocompatibilityStability
spellingShingle Oriyomi Temitayo Ogedengbe
Oluwadamilola Miriam Kolawole
Formulation and evaluation of fluconazole emulgels for potential treatment of vaginal candidiasis
Heliyon
Fluconazole emulgels
Antifungal
Physicochemical
Controlled drug release
In vivo vaginal biocompatibility
Stability
title Formulation and evaluation of fluconazole emulgels for potential treatment of vaginal candidiasis
title_full Formulation and evaluation of fluconazole emulgels for potential treatment of vaginal candidiasis
title_fullStr Formulation and evaluation of fluconazole emulgels for potential treatment of vaginal candidiasis
title_full_unstemmed Formulation and evaluation of fluconazole emulgels for potential treatment of vaginal candidiasis
title_short Formulation and evaluation of fluconazole emulgels for potential treatment of vaginal candidiasis
title_sort formulation and evaluation of fluconazole emulgels for potential treatment of vaginal candidiasis
topic Fluconazole emulgels
Antifungal
Physicochemical
Controlled drug release
In vivo vaginal biocompatibility
Stability
url http://www.sciencedirect.com/science/article/pii/S2405844024042373
work_keys_str_mv AT oriyomitemitayoogedengbe formulationandevaluationoffluconazoleemulgelsforpotentialtreatmentofvaginalcandidiasis
AT oluwadamilolamiriamkolawole formulationandevaluationoffluconazoleemulgelsforpotentialtreatmentofvaginalcandidiasis